Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Connective Tissue Growth Factor Is a Novel Prodepressant.

Turner CA, Sharma V, Hagenauer MH, Chaudhury S, O'Connor AM, Hebda-Bauer EK, Thompson RC, Myers RM, Bunney WE, Barchas JD, Lee FS, Schatzberg AF, Watson SJ Jr, Akil H.

Biol Psychiatry. 2018 Oct 15;84(8):555-562. doi: 10.1016/j.biopsych.2018.04.013. Epub 2018 May 3.

2.

Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals.

Turner CA, Clinton SM, Thompson RC, Watson SJ Jr, Akil H.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):8021-5. doi: 10.1073/pnas.1103732108. Epub 2011 Apr 25.

3.

Fibroblast growth factor 9 is a novel modulator of negative affect.

Aurbach EL, Inui EG, Turner CA, Hagenauer MH, Prater KE, Li JZ, Absher D, Shah N, Blandino P Jr, Bunney WE, Myers RM, Barchas JD, Schatzberg AF, Watson SJ Jr, Akil H.

Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11953-8. doi: 10.1073/pnas.1510456112. Epub 2015 Sep 8.

4.

Interaction between cholecystokinin and the fibroblast growth factor system in the ventral tegmental area of selectively bred high- and low-responder rats.

Ballaz SJ, Perez J, Waselus M, Akil H, Watson SJ.

Neuroscience. 2013;255:68-75. doi: 10.1016/j.neuroscience.2013.09.063. Epub 2013 Oct 9.

5.

DNA methylation in the developing hippocampus and amygdala of anxiety-prone versus risk-taking rats.

Simmons RK, Howard JL, Simpson DN, Akil H, Clinton SM.

Dev Neurosci. 2012;34(1):58-67. doi: 10.1159/000336641. Epub 2012 May 8.

6.

Effects of early-life FGF2 on ultrasonic vocalizations (USVs) and the mu-opioid receptor in male Sprague-Dawley rats selectively-bred for differences in their response to novelty.

Turner CA, Hagenauer MH, Aurbach EL, Maras PM, Fournier CL, Blandino P Jr, Chauhan RB, Panksepp J, Watson SJ Jr, Akil H.

Brain Res. 2019 Mar 14. pii: S0006-8993(19)30142-8. doi: 10.1016/j.brainres.2019.03.011. [Epub ahead of print]

PMID:
30880118
7.

FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.

Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, Guzman D, Li D, Zhang W, Olsen DR, Nguyen VT, Koo CW, Sternlicht MD, Lipson KE.

Pharm Res. 2016 Aug;33(8):1833-49. doi: 10.1007/s11095-016-1918-0. Epub 2016 Apr 8.

8.

FGF2 is a target and a trigger of epigenetic mechanisms associated with differences in emotionality: partnership with H3K9me3.

Chaudhury S, Aurbach EL, Sharma V, Blandino P Jr, Turner CA, Watson SJ, Akil H.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11834-9. doi: 10.1073/pnas.1411618111. Epub 2014 Jul 28.

9.

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.

Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G.

Oncotarget. 2015 Dec 29;6(42):44551-62. doi: 10.18632/oncotarget.6082.

10.

Maternal Style Selectively Shapes Amygdalar Development and Social Behavior in Rats Genetically Prone to High Anxiety.

Cohen JL, Glover ME, Pugh PC, Fant AD, Simmons RK, Akil H, Kerman IA, Clinton SM.

Dev Neurosci. 2015;37(3):203-14. doi: 10.1159/000374108. Epub 2015 Mar 17.

12.

A new role for FGF2 as an endogenous inhibitor of anxiety.

Perez JA, Clinton SM, Turner CA, Watson SJ, Akil H.

J Neurosci. 2009 May 13;29(19):6379-87. doi: 10.1523/JNEUROSCI.4829-08.2009.

13.

Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis.

Ito Y, Goldschmeding R, Bende R, Claessen N, Chand M, Kleij L, Rabelink T, Weening J, Aten J.

J Am Soc Nephrol. 2001 Mar;12(3):472-84.

14.

Selectively Bred Rats Provide a Unique Model of Vulnerability to PTSD-Like Behavior and Respond Differentially to FGF2 Augmentation Early in Life.

Prater KE, Aurbach EL, Larcinese HK, Smith TN, Turner CA, Blandino P Jr, Watson SJ, Maren S, Akil H.

Neuropsychopharmacology. 2017 Jul;42(8):1706-1714. doi: 10.1038/npp.2017.37. Epub 2017 Feb 16.

15.

Connective tissue growth factor and its correlation to other growth factors in experimental granulation tissue.

Inkinen K, Wolff H, Lindroos P, Ahonen J.

Connect Tissue Res. 2003;44(1):19-29.

PMID:
12945801
16.

Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.

Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG.

J Am Soc Nephrol. 2000 Jan;11(1):25-38.

17.

Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: the effect of aspirin treatment.

Makino H, Mukoyama M, Sugawara A, Mori K, Suganami T, Yahata K, Fujinaga Y, Yokoi H, Tanaka I, Nakao K.

Clin Exp Nephrol. 2003 Mar;7(1):33-40.

PMID:
14586741
18.

Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis.

Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, Nakao K.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S134-8.

PMID:
11576939
19.

Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone.

Cheng Y, Rodriguiz RM, Murthy SR, Senatorov V, Thouennon E, Cawley NX, Aryal DK, Ahn S, Lecka-Czernik B, Wetsel WC, Loh YP.

Mol Psychiatry. 2015 Jun;20(6):744-54. doi: 10.1038/mp.2014.136. Epub 2014 Oct 21.

20.

Supplemental Content

Support Center